Podcasts about biden cancer initiative

Send us a textDr. Samir Khleif, MD is CEO of Georgiamune ( https://www.georgiamune.com/team ), a private, science and discovery clinical stage immunotherapeutic biotechnology company focused on reprogramming immune signaling pathways to redirect the immune system to fight diseases.  Dr. Khleif is a pioneer in the field of immunotherapy. He is a medical oncologist, immunologist, innovator, and entrepreneur, as well as a transformational executive in health care and biomedical research.Prior to becoming CEO of Georgiamune, Dr. Khleif served in different academic and leadership positions. He was a National Cancer Institute (NCI)/National Institutes of Health (NIH) scientist and Chief of the NCI Cancer Vaccine Section, where he led the development of pioneering immune-oncology and cancer vaccines into clinical trials. As a national and international academic leader, and detailed by the US government, he served as the founding director and CEO of the King Hussein Cancer Center ( https://www.khcc.jo/en ) in Amman, Jordan, where he led the development of the largest cancer center in the MENA region. He also served as the director of the Georgia Cancer Center, the state cancer center, at Augusta University. He is currently a biomedical scholar and holds a professorship at Georgetown University Medical School.Dr. Khleif also served as a Special Assistant to the Commissioner of the FDA, leading the FDA's Critical Path Initiative for Oncology. He is a member of the board of directors of Ayala Pharmaceuticals and Emerald Biopharmaceutics, and served as a member of the scientific advisory board of more than 20 biotechnology and pharmaceutical companies.Dr. Khleif is an international KOL in immunology and immunotherapy. He has served on many national committees, including the Scientific Advisory Board of the Biden Cancer Initiative, as chair of the Immunotherapy Committee for NRG, and as a member of the NCI Cooperative Group. He currently serves as an advisor for the Parker Institute for Cancer Immunotherapy. Dr. Khleif is an editor of three books, the author of hundreds of peer-reviewed scientific research articles, and a prolific inventor with more than 150 patents issued or pending in the field of immunology and immunotherapy.Dr. Khleif received his medical degree at the University of Jordan, Amman Jordan. He completed his residency in Internal Medicine at the Medical College of Ohio and his fellowship in Medical Oncology at the National Cancer Institute (NCI) in Bethesda, Maryland.#SamirKhleif #Georgiamune #Immunotherapy #KingHusseinCancerCenter #CriticalPathInitiative #FDA #Tregs #RegulatoryTCells #Cancer #Oncology #CheckpointInhibitors #ImmuneEscapeMechanisms #DualFunctioningAntibody #Autoimmune #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast #STEM #Innovation #Science #Technology #ResearchSupport the show

Send us a textDr. Catharine Young, Ph.D. recently served as Assistant Director of Cancer Moonshot Policy and International Engagement at the White House Office of Science and Technology Policy ( https://www.whitehouse.gov/ostp/ ) where she served at OSTP to advance the Cancer Moonshot ( https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative ), with a mission to decrease the number of cancer deaths by 50% over the next 25 years. Dr. Young's varied career has spanned a variety of sectors including academia, non-profit, biotech, and foreign government, all with a focus on advancing science. Dr. Young previously served as Executive Director of the SHEPHERD Foundation, where she championed rare cancer research and drove critical policy changes. Her work has also included fostering interdisciplinary collaborations and advancing the use of AI, data sharing, and clinical trial reform to accelerate cancer breakthroughs.Dr. Young's leadership in diplomacy and innovation includes roles such as Senior Director of Science Policy at the Biden Cancer Initiative and Senior Science and Innovation Policy Advisor at the British Embassy, where she facilitated international agreements to enhance research collaborations. A Presidential Leadership Scholar and TED Fellow, Dr. Young holds a Ph.D. in Biomedical Sciences and completed her post-doctorate work in Biomedical Engineering at Cornell University and is recognized for her ability to bridge science, policy, and advocacy to build sustainable, impactful health ecosystems.#CatharineYoung #OSTP #WhiteHouseOfficeOfScienceAndTechnologyPolicy #CancerMoonshot #SHEPHERDFoundation #BidenCancerInitiative #DepartmentOfDefense #BritishEmbassy #Neurogenetics #AntimicrobialResistance #GlobalHealthSecurityAgenda #OneHealth #RareCancers #ChildhoodCancer #RareDisease #ForeignAndCommonwealthOffice #BiologicalThreats #MitigationStrategies #RiskMitigation #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

On the show today: Lisa Simms Booth is Executive Director at The Smith Center for the Healing Arts and former Senior Director for Patient and Public Engagement at The Biden Cancer Initiative. She is such an extraordinary human being who've I've wanted her on my show for such a long time and, well, here she is. Lisa has this extraordinary way to define and extoll the virtues of cancer survivorship, how far we've come in the last half-century, lessons learned from the pandemic for Nonprofit Leadership, cancer screenings, prevention, and more.FUN FACT: The Smith Center occupies a unique place in my life as they hosted one of the very first Stupid Cancer Happy Hour events in DC in 2007. It's a great place, so if you live in the DC area, be sure to check them out.SIDENOTE: For the cheap seats in the back, many of you may recognize The Smith Center from Episode 81 with my guest, Dr. Julia Rowland, who serves as their Senior Strategic Advisor. (Julia is also the Founding Director of The National Cancer Institute's Office of Cancer Survivorship. You can hear her share her story as one of the contributors to The Cancer Mavericks, our eight-part docu-series about the history of cancer survivorship.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

I was privileged to welcome Dr. Danielle Carnival, White House Cancer Moonshot Coordinator, to the studio. We talked about the President's priorities, principal directives, and legislative strategies, as well as what Americans can look forward to in the coming months and years through this ambitious and transformational National initiative. Carnival, who has a Ph.D. in neuroscience, served as chief of staff and senior policy director for the 2016-2017 White House Cancer Moonshot Task Force. Subsequently, she served as vice president of the Biden Cancer Initiative. She's also a friend of Wegman's. So there's that, too. To learn more about the Whitehouse Cancer Moonshot initiative, visit https://www.whitehouse.gov/cancermoonshot. Enjoy the show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Greg Simon served as the president of the Biden Cancer Initiative from 2017 to 2019. Previously, he was the executive director of the White House Cancer Moonshot Task Force under then Vice President Joe Biden in the Obama administration.Greg has held senior positions in both chambers of Congress, served in two presidential administrations, and was a senior strategy consultant to a variety of international technology CEOs. Greg will be a guest speaker at the 2023 Sonoma Epicurean Event raising funds for the V Foundation. 

I was privileged to welcome Dr. Danielle Carnival, White House Cancer Moonshot Coordinator, to the studio. We talked about the President's priorities, principal directives, and legislative strategies, as well as what Americans can look forward to in the coming months and years through this ambitious and transformational National initiative. Carnival, who has a Ph.D. in neuroscience, served as chief of staff and senior policy director for the 2016-2017 White House Cancer Moonshot Task Force. Subsequently, she served as vice president of the Biden Cancer Initiative. She's also a friend of Wegman's. So there's that, too. To learn more about the Whitehouse Cancer Moonshot initiative, visit https://www.whitehouse.gov/cancermoonshot. Enjoy the show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Sanjay Juneja had the pleasure of talking with Greg Simon, the former President of the Biden Cancer Initiative. Dr. Sanjay and Greg talk about the various dilemmas cancer patients run into and the very real consequences that come as a result. Because of Greg's experience, he sheds light on the serious gap we have of providing proper care and treatment to ALL cancer patients. The good news is that Greg Simon has some plans to radically change the healthcare system for the better!

In 2015, Karen Peterson received a diagnosis of stage 1 triple-negative breast cancer. Soon following, she endured several rough treatments and received the news that she was cancer-free, but she was still worried cancer would make a devastating return. She spent the next year researching different treatments, clinical trials, and care teams. Founder and Chief Patient Advocate of Karen's Club, https://www.karensclub.org/ , Karen Peterson were inspired to help other patients of color understand the complex, confusing world of clinical trials. A Stage IV Triple Negative breast cancer survivor, Karen is a founding member of Foundation Medicine's Patient Community Council, consultant for Blue Note Therapeutics, and a Cancer Research Institute – Immuno Advocate. Karen was the featured patient speaker at the Biden Cancer Initiative's 2019 presentation at ASCO, and the 2020 Inaugural AACR Cancer Disparities Progress Report presented to Congress. Her inspiring story has been shared with Cure, Essence, Health, and People magazines as well as ABC Radio Networks “Perspective” and The Today Show. In 2021, Karen successfully completed the exclusive Robin Hood/Blue Ridge Labs Fellowship Program. Now she's working on a stand-up comedy routine! --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/diane-winbush/support

Biden-Cancer Initiative intro and wrap.

Biden-Cancer Initiative intro and wrap.

On the show today: Lisa Simms Booth is Executive Director at The Smith Center for the Healing Arts and former Senior Director for Patient and Public Engagement at The Biden Cancer Initiative. She is such an extraordinary human being who've I've wanted her on my show for such a long time and, well, here she is. Lisa has this extraordinary way to define and extoll the virtues of cancer survivorship, how far we've come in the last half-century, lessons learned from the pandemic for Nonprofit Leadership, cancer screenings, prevention, and more.FUN FACT: The Smith Center occupies a unique place in my life as they hosted one of the very first Stupid Cancer Happy Hour events in DC in 2007. It's a great place, so if you live in the DC area, be sure to check them out.SIDENOTE: For the cheap seats in the back, many of you may recognize The Smith Center from Episode 81 with my guest, Dr. Julia Rowland, who serves as their Senior Strategic Advisor. (Julia is also the Founding Director of The National Cancer Institute's Office of Cancer Survivorship. You can hear her share her story as one of the contributors to The Cancer Mavericks, our eight-part docu-series about the history of cancer survivorship.For more information, visit https://OffScripMedia.com and follow @MZOutofPatients, @MatthewZachary, @VaxOnPod, and @OffScripMedia on Twitter.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Greg Simon, former president of the Biden Cancer Initiative and former executive director of the White House Cancer Moonshot Task Force, discusses his long career in healthcare that has cut across the government, nonprofit, and private sectors. His work has extended from FasterCures, which has sought to build a patient-centric system to accelerate the development of therapies to the healthcare investment platform Poliwogg, which sought to democratize healthcare investing. Neil speaks to Greg about what he's learned from his work, the themes that unified his career, and his own cancer diagnosis has changed his perspective

Americans are an abnormally generous bunch. Individual citizens donate an impressive amount of their time and money to helping others. When you give to a cause, you do so because the organization will, you know, invest money towards that cause. If you are one of the people who contributed some of the $4,800,000 to the Biden Cancer Initiative, you paid for some really fat executive salaries, a great deal of first class travel and a bunch of fun networking events that you can bet were open bar at 5 star hotels overlooking private golf courses or glorious beaches. What you did NOT pay for was so much as an Erlenmeyer flask, pipette or litmus test. Tune in as we help you better spend your donation dollars. And check reliable third party sources like www.charitywatch.org, who provide detailed clarity into how charitable organizations spend the money they raise. --- Send in a voice message: https://anchor.fm/messytimes/message Support this podcast: https://anchor.fm/messytimes/support

In this episode of American Uproar, we discuss the "there is no fraud" with multiple news stories coming to light about recent election frauds well as the questionable fund details surrounding the Biden Cancer Initiative foundation. Visit our online shop! www.americanpodcasting.net/shopBecome a Patreon! www.patreon.com/americanuproarListen to our other shows! www.americanpodcasting.net/shows

A cancer charity started by Joe Biden gave out no money to research, and spent most of its contributions on staff salaries, federal filings show.The Biden Cancer Initiative was founded in 2017 by the former vice president and his wife Jill Biden to “develop and drive implementation of solutions to accelerate progress in cancer prevention, detection, diagnosis, research and care and to reduce disparities in cancer outcomes,” according to its IRS mission statement. But it gave out no grants in its first two years, and spent millions on the salaries of former Washington DC aides it hired.The charity took in $4,809,619 in contributions in fiscal years 2017 and 2018, and spent $3,070,301 on payroll in those two years. The group’s president, Gregory Simon, raked in $429,850 in fiscal 2018 (July 1, 2018 to June 30, 2019), according to the charity’s most recent federal tax filings.Simon, a former Pfizer executive and longtime health care lobbyist who headed up the White House’s cancer task force in the Obama administration, saw his salary nearly double from the $224,539 he made in fiscal 2017, tax filings show.Danielle Carnival, former chief of staff for Obama’s cancer initiative, the Cancer Moonshot Task Force, who took home $258,207 in 2018.The charity spent $56,738 on conferences and $59,356 on travel that year. The following year, the travel expenditure swelled to $97,149, and the non-profit spent $742,953 on conferences, tax filings show.But under grants distributed, it listed zero.Simon had said that the main point of the charity was not to give out grants, and that its goal was to find ways to accelerate treatment for all, regardless of their economic or cultural backgrounds.Biden headed up the Cancer Moonshot Task Force when he was veep after his son Beau died of a brain tumor in 2015. After leaving office, the Biden Cancer Initiative sought to continue such efforts to provide “urgent” solutions to treating cancer, according to a 2017 press statement announcing its launch.The Bidens stacked the board with leading oncologists and celebrity cancer survivors, including musician Jimmy Gomez from the Black Eyed Peas.After only two years, the charity “paused” its operations when Biden and his wife stepped down for Joe Biden’s presidential run.Although the organization is still officially active, according to the IRS, Simon said in a 2019 interview that without the Bidens at the helm, the charity lost its edge.“We tried to power through but it became increasingly difficult to get the traction we needed to complete our mission,” he told the AP in July 2019.Neither Simon nor Biden could be reached for comment last week.Article: https://nypost.com/2020/11/14/biden-cancer-initiative-spent-millions-on-payroll-zero-on-research-report/Please consider in donating to the program:DONATE: https://paypal.me/RocciStucciMugs, Hats, and Apparel:Merch: https://www.etsy.com/shop/rsmediashopGet you CBD and Skin Care Products with Verve!! Use Code: VERVE50 for 50% off you order!Verve Forever (CBD) https://bit.ly/2QIDBJNKickAss Beef Jerky (Code: meatball for 10% off) https://kickassbeefjerky.comRocci's Private FB: https://www.facebook.com/RocciStucciSrRocci Stucci Media FB Page: https://www.facebook.com/RocciStucciMediaPODCAST PAGE:Spreaker The SitRoom: https://www.spreaker.com/show/rocci-stuccis-situation-roomSpreaker EBN Talk Radio: https://www.spreaker.com/show/everything-but-normal-talk-radio

In this episode, sponsored by Thermo Fisher Scientific, we’re taking a look at how genomic technologies are transforming cancer care - now and in the future, and the importance of making sure that these advances are available to all.With:- Greg Simon, past president of the Biden Cancer Initiative and former executive director of the White House Cancer Moonshot Task Force.- Jim Downing - president and CEO of St Jude Children’s Research Hospital- Dr Marianne Grantham, Head of Cytogenetics and Molecular Haematology department at the Royal London Hospital- Kim Wood, Thermo Fisher Scientific’s Clinical Sequencing DivisionFull show notes, transcript, music credits and references online at GeneticsUnzipped.com.Follow us on Twitter @GeneticsUnzipGenetics Unzipped is written and presented by Kat Arney with audio production by Hannah Varrall.This podcast is produced by First Create the Media for the Genetics Society - one of the oldest learned societies in the world dedicated to supporting and promoting the research, teaching and application of genetics.

On today’s show, returning champion Dr. Catharine Young, former Senior Director of Science Policy at the Biden Cancer Initiative, and current Executive Director at the SHEPHERD foundation. A human of many hats, she’s also a TED Fellow, Presidential Leadership Scholar, and Doctor of Philosophy with one of the most awesomely sardonic Twitter feeds around @CatYoung. Catharine was one of my very first guests on the program, SO if you want to hop in your Delorean and check out Episode 5 from March 26th. This time around, we talk COVID-ish stuff, pivoting your nonprofits in a crisis, helping scientists learn to speak “person,” the egregious misgivings of confirmation bias during a pandemic, and how the science of ophthalmology must change perfect vision to 2019 or 2021 because 2020 is dead to us and there forever shall no longer be hindsight as we know it.

The Learning Community Series at The New School Join TNS Host Michael Lerner in a webinar conversation with Lisa Simms Booth, the executive director at the Smith Center for Healing and the Arts. The Smith Center is a Washington, DC-based health, education, and arts nonprofit that develops and promotes physical, emotional, and mental resources for people affected by cancer. Lisa Simms Booth: In addition to serving as executive director for the Smith Center for Healing and the Arts, Lisa previously served as senior director of patient and public engagement at the Biden Cancer Initiative. Prior to joining the Initiative, she was at FasterCures, a center of the Milken Institute, playing leadership roles in partnership development, external affairs and operations. Lisa’s experience also includes working for political and advocacy organizations including LISTEN, Inc., The Alliance for Justice, Time Dollar Institute, Children’s Defense Fund, Democratic National Committee and the National Rainbow Coalition.

Dr. Catharine Young has always been drawn to tackling big problems. She currently serves as the Executive Director for the Shepherd Foundation, an organization which seeks to build a movement to revolutionize treatment, care and education for rare cancer patients and their families. Catharine has also always been drawn to science - the thread that ties her career journey together. She holds a PhD in Biomedical Sciences, with postdoctoral training in Biomedical Engineering at Cornell University. She has worked at both the US and foreign government level as well as the non-profit startup space. Her previous position was at the Biden Cancer Initiative where she served as the Senior Director of Science Policy. Her awards include being selected as a Presidential Leadership Scholar, TED Fellow and Social Enablers top 100 most inspiring social entrepreneurs. Catharine is a staunch advocate for women in science and science communication and is the founder of Supper with a Scientist, a grassroots effort to develop strong relationships between scientists and the public.

Vice President of Google Health, Dr. David Feinberg, talks with StartUp Health Chief Medial Officer, Howard Krein, MD, PhD, on the main stage of the StartUP Health Festival in San Francisco. January 14, 2020. Dr. David Feinberg has spent his entire career caring for people's health and wellbeing. And after years in the healthcare system, he now leads Google Health, which brings together groups from across Google and Alphabet that are using AI, product expertise and hardware to take on big healthcare challenges. (https://www.blog.google/technology/he...) Dr. Howard Krein is the Chief Medical Officer of StartUp Health, which was founded in 2011 to invest in a global army of entrepreneurs, called Health Transformers, committed to achieving health moonshots. Dr. Krein is also an Assistant Professor of Otolaryngology: Head & Neck Surgery at Thomas Jefferson University and a founding partner and co-director of Jefferson's Facial Aesthetic and Reconstructive Center. Additionally, he is the Senior Director of Health Policy & Innovation at the Sidney Kimmel Cancer Center. From 2017 to 2019, Dr. Krein served on the Biden Cancer Initiative's Board of Directors. Dr. Krein is part of an exclusive group of physicians with two doctorates, receiving his MD from Thomas Jefferson Medical College in Philadelphia and a PhD in Cell and Developmental Biology from UMDNJ/Robert Wood Johnson Medical School. Dr. Krein completed internships in both Emergency Medicine and General Surgery, a residency in Otolaryngology: Head and Neck Surgery at Thomas Jefferson University Hospital in Philadelphia and a Fellowship in Facial Plastic and Reconstructive Surgery at Medical College of Virginia in Richmond Virginia. He earned his Bachelor's degree in Biology and a Master's degree in Neuroscience from Rutgers University. Dr. Krein lives in Philadelphia, PA. Entrepreneurs: How to get investment from StartUp Health https://www.startuphealth.com/ Investors: How to invest in StartUp Health Moonshots http://www.healthmoonshots.com Want more content like this? You can subscribe to the podcast as well as other health innovation updates at startuphealth.com/content. Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox.

Dr. Jill Biden, Co-Chair, Biden Cancer Initiative, Former Second Lady of the United States, presents this keynote conversation, "Together We Can End Cancer" at the 2019 StartUp Health Festival in San Francisco, California. Moderated by Dr. Howard Krein, Chief Medical Officer, StartUp Health. Entrepreneurs: How to get investment from StartUp Health https://www.startuphealth.com/ Investors: How to invest in StartUp Health Moonshots http://www.healthmoonshots.com Want more content like this? You can subscribe to the podcast as well as other health innovation updates at startuphealth.com/content. Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox.

With the care of patients with cancer strewn across numerous settings, are electronic health records (EHRs) meeting the definition of interoperability according to the 21st Century Cures Act? Dr. Pennell speaks with author Wendy Rubinstein. Read the related article "CancerLinQ: Cutting the Gordian Knot of Interoperability" on JOP.   Hello and welcome to the ASCO Journal of Oncology Practice podcast. This is Dr. Nate Pennell, medical oncologist at the Cleveland Clinic and consultant editor for the JOP. Most oncologists in America today use an electronic medical record, or EMR. But for a number of reasons, few of us are able to access records for patients outside of our own practice, a concept that's known as interoperability. Today we're going to be talking about a new editorial published as part of a series called "The State of Cancer Care in America." This editorial is titled "CancerLinQ-- Cutting the Gordian Knot of Interoperability," published in the January 2019 issue of the JOP. Joining me on this podcast is the author Dr. Wendy Rubinstein medical geneticist and Deputy Medical Director at CancerLinQ, LLC. Dr. Rubinstein, thank you for joining me today. Thanks for having me. So I know that this is not going to be a surprise to any of our listeners, but would you mind just kind of giving us a little background on the issue of EHR interoperability, and how did we end up with the scenario that we have today? Well, sure. Of course, electronic health records systems weren't built with interoperability in mind. The overarching goal for hospitals was documentation to support billing, and it hasn't been a priority for hospitals to make it easy for their patients to interact with other health systems. But to be fair, people didn't talk much about interoperability 10 to 15 years ago. And I'm not even sure an official definition existed. So now the 21st Century Cures Act provides a definition. So basically, electronic health information should be able to be securely exchanged with other health information technology. And there should be no special effort required by the user, especially and including patients. And the data exchange for the authorized use, it needs to be completely enabled under applicable laws, and any information blocking is prohibited. So what this comes down to, basically, is that a patient should be able to have care at one medical office, and then go to a separate system across town, without having to fill out another paper form with their complete medical history, medication list, and review of systems all over again. So part of the article talks about, and you mentioned, the ASCO Oncology Practice Census. And in 2017, the practice census found that 40% of practices were unable to accept any patient information from other practices. And you might think that the problem is getting better with attention to it, but actually, it's getting worse. In the 2016 practice census, 34% of oncology practices said that their EHR was interoperable with hospitals in their region. But in 2017, only 10% were interoperable with regional hospitals. So in oncology, this is especially important because cancer patients typically have their care strewn across multiple specialists, surgery, radiation oncology, medical oncology, and more. So with their care being decentralized and being complex, how can we really subject our patients to recounting their entire history every time they come to a new specialist? And we're relying on them to be savvy about their cancer history and to be accurate about it. And this is often the worst time of their life. So without quite saying it to them, we're basically letting them know that we don't communicate with our other doctors. And I have to say, sometimes my own medical profession embarrasses me. Yeah, it's interesting. I mean, it's a couple of different issues, the first being of just simple interoperability and having access to your patients' records when they're not within your system. The traditional way of doing this is you've typed up a letter or a note from what you've done, and then you mail it to the other physicians who are either the primary care doctor or the person who referred to you the patient. And strangely enough, that's still mostly how this happens. I have a sophisticated electronic medical record that puts together a sophisticated note filled with all kinds of important information, which gets printed out and put it in an envelope and mailed to someone, rather than sending that electronically and having it available whenever they need it. They have to somehow come up with a way to scan that into their system so that they can read it. So it's really remarkable that we're still in that system. And I now have limited interoperability with other people through my own EMR, and it's just astonishing how much easier it is to keep track of people with that. Once you start to get a taste of the potential of that, it's really hard to go back and not be able to access patient's records anymore. Everyone I think is a little bit aware of this issue and becoming increasingly aware of this issue. What are the barriers out there to making EHRs interoperable? It just seems like such an obvious thing to do, and yet it somehow is a difficult process. To attempt to maybe take something complex and bring it to some basic issues, I can call out a couple of issues. One is extreme customization, and the other is that we need a common language that can speak across different implementations of electronic health records. So with extreme customization, and this is how I would characterize it. So customization is very effective at locking up health information and preventing it from being exchanged. And for any EHR vendor, offering a way for clinicians to customize their reports, their documentation, it really is a great way to satisfy them. And in fact in my own experience, my cancer genetics practice became very efficient by creating templates for notes and letters about genetic testing and managing patients at high risk of cancer. But if you think about it, when I recorded a diagnosis of colon cancer in a letter to the patient or the clinician, it wasn't mapped to any standard vocabulary or code. It can't be shared other than as a TXT file. When you talked about bringing in scanned documents, yes, you can look at them, but they're not machine computable. In fact, if you like to know how many ways you can say total neutrophil count in an electronic health record, CancerLinQ was in the unfortunate position of figuring this out. So in the first 30 oncology practices that CancerLinQ received data from, there were 76 distinct ways to say total neutrophil count, like white blood cell count or WBC. And that means that there were more than two names per organization on average, even within an organization. There's no agreement on what to call this. So it's certainly true. We, as human beings, we can all semantically process different terms for total neutrophil count, but a computer can't. It can't do that, unless we provide a mapping or we create it. So this basically locks up the data and reduces its value. So to extract the value, we apply natural language processing and human observation using interfaces. But that's expensive, and the problem is it doesn't help at the source. You still have the EHR, it's not really aggregated together yet, and in the day to day workings, you're not really doing anything to solve the problem. So the other problem which is very much related is we need a lingua franca. We need a common language to make the proper use of the data that we have in EHRs. And so on a higher level, ASCO and CancerLinQ have convened a volunteer stakeholder group, and this represents diverse perspectives in oncology, different specialties coming to the table. And the purpose is to create a core set of data elements from oncology called mCODE. So mCODE stands for Minimal Common Oncology Data Elements. And ASCO is aligned with other medical organizations, as well, and the Biden Cancer Initiative, so that together we can inform oncology EHR vendor design. We can inform their decisions and, hopefully, prompt interoperability to improve cancer care. One of the things that's-- of course, you now work with CancerLinQ. Can you tell us just a little bit about CancerLinQ and how CancerLinQ can work to overcome some of these issues? Sure, I'd love to. So CancerLinQ is a major initiative at ASCO. And the goal was to create a learning health system for oncology. So first and foremost, CancerLinQ is a quality measurement and reporting system. We have over 100 health care organizations. These are large and small, they're community and academic, that are participating in CancerLinQ. And so far, we've established data flows with 47 organizations, and we've integrated data for over a million patients with cancer. And that reflects their comprehensive longitudinal record of health. So by doing this, the reason to do this is we're enabling practicing oncologists to measure, and report, and improve the quality in patient care. So when you look at, for example, the 2017 ASCO Oncology Practice Census, about 25% to 30% of practices, they called out quality measurement and reporting activities as a top burden for them. In order for them to do this, they have to actually do manual extraction from electronic health records, if you can wrap your mind around that. You have to pay to do that. So the CancerLinQ platform reduces the reporting burden by displaying the quality measures for MIPS, MACRA reporting and also supports ASCO's QOPI certification. And what this means is that clinicians can actually see the time window they have left to take specific actions to meet the quality benchmarks. The other part of CancerLinQ is that we provide statistically de-identified data sets from the cohort to researchers and to FDA. And in that way, we're trying to accelerate discovery and scientific improvements to cancer care. Yeah, it's a fantastic initiative, and I'm glad to see that it seems to be growing and doing well. The next question would be, how can CancerLinQ, aside from individual practices being able to use the data for quality metrics and, of course, the anonymized pool data for research, how is this working to overcome problems of interoperability? So CancerLinQ is somewhat unique in that we've integrated data from practices, so far using seven different electronic health records. So we don't limit, we feel we can't limit the data aggregation to a single EHR type because the overall goal is to learn from all patients. But there are some common problems that we share with other big data providers. So any entity that's performing data aggregation, they're also coming up against the same problem we have, as needing a common language for oncology, such as mCODE. And as I mentioned, ASCO is looking to engage everyone who has this common problem to solve it together. One barrier I can't resist talking about as a geneticist is the way genomic data is handled. The one disturbing practice is that really the way DNA sequencing data exists is it's completely structured in machine computable when it comes off the sequencer. I mean, almost by definition. And then the results get reported by paper, and even if there is an electronic file sent to the practitioner with the report, there's nowhere in the electronic health record to store the genetic test data in its rich detail. So the report might get scanned or copied someplace, and it'll get attended somewhere where you can go visualize it. If it's scanned in, it loses all of its structure, and then it requires optical character recognition and very messed up tables to try to make sense. So if you think about it, like what we want to do with that data, how can we automatically run clinical quality measures for colon cancer without having a place for KRAS gene test results? That's already in all the quality measures. If an oncology practice is running Molecular Tumor Board, how can they do that with reading off of this piece of paper? They need the files to really run that activity. And the same thing is true for identifying patients who are eligible for a clinical trial, increasingly based on a molecular variant result. So we can do that to some extent. We can do all these things, but we really can't scale precision oncology with these kinds of limitations. So I think a common theme across CancerLinQ and other entities that are trying to aggregate data and especially to combine it with the rich phenotypic data in electronic health records, the molecular diagnostics laboratory should routinely make these results available to the ordering clinicians as structured data files. It may be difficult for them to maintain it themselves. The electronic health record really should have a place for this, which with mCODE, that will definitely be a part of mCODE. Where do we go from here? How do we get from where we are today to the world where all this information is easily shareable across EHRs? The technical challenges there, but really it's about collaboration and having a will to solve this across the entire ecosystem. So we have created an organization called the Oncology Leadership Council. So CancerLinQ's Oncology Leadership Council includes corporate nonprofit and government collaborators and, for example, the American Society for Radiation Oncology, National Cancer Institute, FDA, the Cancer Informatics for Cancer Centers, Ci4CC, AstraZeneca, College American Pathologists, American College of Medical Genetics and Genomics, and many others. Now ASCO doesn't think that this is something that we could or should solve alone. This really means helping the entire oncology community to improve care by solving the problem at the source. And that means capture all of the important oncology data as structured, computable information. And we have to do this without imposing any more documentation burdens on physicians. And frankly, we shouldn't really be hiring an army of data entry clerks to do this either. I like to think about call to action. What can people do, given the situation? So I would like the listeners to know that the Office for the National Coordinator for Health IT is right now soliciting comments on what they call the strategy on reducing regulatory and administrative burden relating to the use of health IT and EHRs. So ASCO is currently preparing comments, and you'll have a chance to review and provide feedback. And I also wanted to let listeners know that you can also participate in the writing of comments, which is going on by the American Medical Informatics Association, AMIA. The comments are due soon, on January 28, 2019, but input would be very valuable. I'd also like to mention that CancerLinQ is concerned about information blocking. And as I mentioned before, information blocking is prohibited by ONC. And lastly, I can't resist inviting people, that if you're interested in joining CancerLinQ, please contact us. Excellent. I think that was a good idea to put that message out there. And I will also put the plug in that joining CancerLinQ is actually free of cost to get this wonderful resource. You bet. Dr. Rubinstein, thank you so much for talking with me today. Thank you, it's a great opportunity and a real pleasure. And I also want to thank our listeners out there who joined us for this podcast. The full text of Dr. Rubinstein's paper, "CancerLinQ-- Cutting the Gordian Knot of Interoperability," is available online now at ASCOpubs.org, backslash journal, backslash JOP in the January 2019 issue. This is Dr. Nate Pennell for the Journal of Oncology Practice signing off.

Greg Simon, President at the Biden Cancer Initiative and Former Executive Director of the White House Cancer Task Force will reflect on the work of the Cancer Moonshot. Which provided the leadership to harness the millions of scientists and patients, powerful new therapies, and cultural changes needed to double our rate of progress against cancer.  He will also provide a progress report on the Biden Cancer Initiative which is now continuing this movement to double our rate of progress in preventing, detecting, diagnosing and treating cancer. This session was presented at the 4th annual Immuno-Oncology 360 conference in February 2018. For the latest news in immunotherapy, join us at the 5th annual IO360 conference taking place February 6-8, 2019 in New York, NY.

Vice President Joe Biden sits down with Jon, Jon, and Tommy at his office in Washington, DC to talk about Donald Trump, John Bolton, partisanship, the economy, and the Biden Cancer Initiative.

With Special guests: Alex Lawson (Executive Director of Social Security Works), Dave McCullough (conservative strategist) and Greg Simon (President of Biden Cancer Initiative)

This week, the top managed care news included the Senate announcing it would delay voting on the healthcare bill until after July 4; the FDA outlined a plan to expedite drug approvals; and Joe and Jill Biden launched the Biden Cancer Initiative.

In his final State of the Union address, President Obama asked Vice President Biden to head up the “Cancer Moonshot” to end cancer as we know it. Our next guest, Greg Simon was named the Executive Director of this Initiative, leading a team of professionals to seek out unprecedented advances in cancer prevention, diagnosis, and treatment. Greg's work supported the passage of the “21st Century Cures Act” on December 7, 2016, providing $1.8 billion for the Cancer Moonshot over the next seven years. In this fascinating discussion, Greg explains the steps necessary to make a Moonshot Initiative succeed by harnessing the resources of government, academia, non-profits, and the private sector in the fight against cancer. Greg illuminates how we can all bring together diverse groups of people to create movements that solve the world's biggest problems. Please enjoy our conversation with Greg Simon. And remember to visit IVY.com to enjoy access to a lifetime of learning, growth, and impact through in-person collaborations with world-class leaders, thinkers, and institutions. -- This episode of the IVY Podcast is brought to you by Eight, maker of the Eight Smart Bed. The Eight Smart Bed is a four layer high density foam mattress paired with a smart cover that goes on the mattress just like a fitted sheet. This nearly invisible technology layer has multiple sensors that measure the quality of your sleep and deliver a daily sleep report each morning through the Eight app. The Eight cover also has a bed warming feature that warms each side of the bed individually to accommodate different sleeping temperatures. And Eight connects to almost any wifi enabled device in your house. Coffee makers, blinds, smart lights, did we mention bed warming? IVY Podcast listeners get $100 off any mattress purchase by entering the promo code IVY at checkout — visit www.eightsleep.com/ivy to start sleeping smarter today!  

Greg Simon, Director of the Biden Cancer Initiative and previously the Executive Director of the White House Cancer Moonshot Task Force, discusses the impetus behind Cancer Moonshot and how the public and private sectors can collaborate to accelerate progress toward cancer cures.

Nikolai DiPippa, Clinton School Director of Public Programs, sat down with Greg Simon, Director of Biden Cancer Initiative at the Biden Foundation. Previously, he was the Executive Director of the White House Cancer Moonshot Taskforce. A position created by President Barack Obama for which he was chosen by Vice President Joe Biden in March of 2016. As Executive Director, he assembled and lead a team of eight professionals to support the work of the Vice President in developing and promoting the goals of the Cancer Moonshot. He also coordinated the work of the taskforce comprised of twenty cabinet and subcabinet offices.